DLL3-EXPRESSING TUMORS
Clinical trials for DLL3-EXPRESSING TUMORS explained in plain language.
Never miss a new study
Get alerted when new DLL3-EXPRESSING TUMORS trials appear
Sign up with your email to follow new studies for DLL3-EXPRESSING TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising cancer drug tarlatamab tested in new tumor types
Disease control Recruiting nowThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with advanced DLL3-expressing cancers will receive tarlatamab and be monitored for response and …
Matched conditions: DLL3-EXPRESSING TUMORS
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
New scan could spot hidden cancers more clearly
Diagnosis Recruiting nowThis study tests a special PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine cancer will …
Matched conditions: DLL3-EXPRESSING TUMORS
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated May 26, 2026 09:03 UTC